Literature DB >> 31097391

Understanding the mechanisms of reversal of type 2 diabetes.

Roy Taylor1, Ahmad Al-Mrabeh2, Naveed Sattar3.   

Abstract

Clinical and pathophysiological studies have shown type 2 diabetes to be a condition mainly caused by excess, yet reversible, fat accumulation in the liver and pancreas. Within the liver, excess fat worsens hepatic responsiveness to insulin, leading to increased glucose production. Within the pancreas, the β cell seems to enter a survival mode and fails to function because of the fat-induced metabolic stress. Removal of excess fat from these organs via substantial weight loss can normalise hepatic insulin responsiveness and, in the early years post-diagnosis, is associated with β-cell recovery of acute insulin secretion in many individuals, possibly by redifferentiation. Collectively, these changes can normalise blood glucose levels. Importantly, the primary care-based Diabetes Remission Clinical Trial (DiRECT) showed that 46% of people with type 2 diabetes could achieve remission at 12 months, and 36% at 24 months, mediated by weight loss. This major change in our understanding of the underlying mechanisms of disease permits a reassessment of advice for people with type 2 diabetes.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31097391     DOI: 10.1016/S2213-8587(19)30076-2

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   32.069


  44 in total

1.  Pancreaticoduodenectomy model demonstrates a fundamental role of dysfunctional β cells in predicting diabetes.

Authors:  Teresa Mezza; Pietro Manuel Ferraro; Gianfranco Di Giuseppe; Simona Moffa; Chiara Ma Cefalo; Francesca Cinti; Flavia Impronta; Umberto Capece; Giuseppe Quero; Alfredo Pontecorvi; Andrea Mari; Sergio Alfieri; Andrea Giaccari
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 14.808

2.  BACH2 inhibition reverses β cell failure in type 2 diabetes models.

Authors:  Jinsook Son; Hongxu Ding; Thomas B Farb; Alexander M Efanov; Jiajun Sun; Julie L Gore; Samreen K Syed; Zhigang Lei; Qidi Wang; Domenico Accili; Andrea Califano
Journal:  J Clin Invest       Date:  2021-12-15       Impact factor: 14.808

Review 3.  Intra-pancreatic fat deposition: bringing hidden fat to the fore.

Authors:  Maxim S Petrov; Roy Taylor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-12-08       Impact factor: 46.802

4.  Body weight and metabolic risk factors in patients with type 2 diabetes on a self-selected high-protein low-carbohydrate diet.

Authors:  Ahmad H Alzahrani; Mads J Skytte; Amirsalar Samkani; Mads N Thomsen; Arne Astrup; Christian Ritz; Elizaveta Chabanova; Jan Frystyk; Jens J Holst; Henrik S Thomsen; Sten Madsbad; Steen B Haugaard; Thure Krarup; Thomas Meinert Larsen; Faidon Magkos
Journal:  Eur J Nutr       Date:  2021-06-08       Impact factor: 5.614

Review 5.  Normal and defective pathways in biogenesis and maintenance of the insulin storage pool.

Authors:  Ming Liu; Yumeng Huang; Xiaoxi Xu; Xin Li; Maroof Alam; Anoop Arunagiri; Leena Haataja; Li Ding; Shusen Wang; Pamela Itkin-Ansari; Randal J Kaufman; Billy Tsai; Ling Qi; Peter Arvan
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

6.  The effects of beta-cell mass and function, intercellular coupling, and islet synchrony on [Formula: see text] dynamics.

Authors:  Maryam Saadati; Yousef Jamali
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

Review 7.  Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador.

Authors:  Jaime Guevara-Aguirre; Camila Bautista; Carlos Torres; Gabriela Peña; Carolina Guevara; Cristina Palacios; Alexandra Guevara; Antonio W D Gavilanes
Journal:  Rev Endocr Metab Disord       Date:  2020-10-12       Impact factor: 6.514

Review 8.  Diet and exercise in the prevention and treatment of type 2 diabetes mellitus.

Authors:  Faidon Magkos; Mads F Hjorth; Arne Astrup
Journal:  Nat Rev Endocrinol       Date:  2020-07-20       Impact factor: 43.330

9.  Natural Compound 3β,7β,25-trihydroxycucurbita-5,23(E)-dien-19-al from Momordica charantia Acts as PPARγ Ligand.

Authors:  Nur Adelina Ahmad Noruddin; Mohamad Faiz Hamzah; Zulfadli Rosman; Nurul Hanim Salin; Alexander Chong Shu-Chien; Tengku Sifzizul Tengku Muhammad
Journal:  Molecules       Date:  2021-05-03       Impact factor: 4.411

Review 10.  Type 2 diabetes and remission: practical management guided by pathophysiology.

Authors:  Roy Taylor
Journal:  J Intern Med       Date:  2020-12-27       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.